¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"antigenic gain"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • acoustic gain
    À½ÇâÁõÆø
  • gain
    1. ȹµæ, À̵æ 2. Áõ°¡ 3. ÁõÆø
  • oxygen gain factor
    »ê¼ÒÀ̵æ°è¼ö
  • weight gain
    üÁßÁõ°¡
  • antigenic deletion
    Ç׿ø°á¼Õ
  • antigenic determinant
    Ç׿ø°áÁ¤ÀÎÀÚ
  • antigenic diversion
    Ç׿øÀüȯ
  • antigenic drift
    Ç׿øº¯ÀÌ
  • antigenic profile
    Ç׿øÇÁ·ÎÇÊ
  • antigenic reversion
    Ç׿øº¹±Í
  • antigenic shift
    Ç׿øº¯À§
  • antigenic specificity
    Ç׿øÆ¯À̼º
  • antigenic stimulation
    Ç׿øÀÚ±Ø
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • gain
    ȹµæ, À̵æ, Áõ°¡, ÁõÆø
  • antigenic determinant
    Ç׿ø°áÁ¤±â
  • antigenic specificity
    Ç׿øÆ¯À̼º
  • antigenic stimulation
    Ç׿øÀÚ±Ø
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • acoustic gain
    À½ÇâÁõÆø
  • oxygen gain factor
    »ê¼ÒÀ̵æ°è¼ö
  • therapeutic gain factor
    Ä¡·áÀ̵æ°è¼ö
  • gain
    ȹµæ, À̵æ, Áõ°¡, ÁõÆø
  • weight gain
    üÁßÁõ°¡
  • antigenic deletion
    Ç׿ø°á¼Õ
  • antigenic determinant
    Ç׿ø°áÁ¤±â
  • antigenic diversion
    Ç׿øÀüȯ
  • antigenic drift
    Ç׿ø¼ÒÆøº¯ÀÌ
  • antigenic profile
    Ç׿øÇÁ·ÎÇÊ
  • antigenic reversion
    Ç׿øº¹±Í
  • antigenic shift
    Ç׿øº¯À§
  • antigenic specificity
    Ç׿øÆ¯À̼º
  • antigenic stimulation
    Ç׿øÀÚ±Ø
  • antigenic transformation
    Ç׿øº¯È¯
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • AGC (automatic gain control)
    ÀÚµ¿ °ÔÀÎ Á¶Àý
  • AGC (automatic gain control)
    ÀÚµ¿ (í»ÔÑ) °ÔÀÎ Á¶Àý (ðàï½), À̵æÀÚµ¿Á¶Àý
  • T.G.C (time gain compensation)
    ½Ã°£ (ãÁÊà) °ÔÀÎ º¸»ó (ÜÍßÁ), °Å¸®(±íÀÌ) °ÔÀÎ º¸»ó
  • T.G.C (time gain compensation)
    ½Ã°£ °ÔÀÎ º¸»ó
  • acoustic gain
    À½Çâ ÁõÆø
  • gain
    °ÔÀÎ
  • primary gain
    ÀÏÂ÷(Àû) À̵æ(ìéó­îÜì¦Ôð).
  • antigenic
    Ç׿ø¼º(¡­àõ)(ÀÇ).
  • antigenic
    Ç׿ø¼º(ÀÇ)
  • antigenic assay
    Ç׿ø¼ººÐ¼®
  • antigenic competition
    Ç׿ø°æÀï
  • antigenic deletion
    Ç׿ø°á½Ç(ù÷ê«ÌÀã÷).
  • antigenic determinant
    Ç׿ø°áÁ¤±â(¡­Ì½ïÒÐñ).
  • antigenic determinant
    Ç׿ø°áÁ¤±â(¡­Ì½ïÒÐñ).
  • antigenic determinant
    Ç׿ø°áÁ¤±â(¡­Ì½ïÒÐñ).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • acoustic gain
    À½Çâ ÁõÆø
  • depth gain compensation
    ±íÀÌ °ÔÀÎ(°­µµ) º¸»ó
  • far gain
    ¿ø°Å¸® °ÔÀÎ
  • far gain
    ¿ø°Å¸® (êÀËå×î) °ÔÀÎ
  • gain
    °ÔÀÎ
  • near gain
    ±Ù°Å¸® °ÔÀÎ
  • near gain
    ±Ù°Å¸® (ÐÎËå×î) °ÔÀÎ
  • oxygen gain factor (OGF)
    »ê¼ÒÀ̵æ°è¼ö
  • primary gain
    ÀÏÂ÷(Àû) À̵æ(ìéó­îÜì¦Ôð).
  • secondary gain
    ÀÌÂ÷¼º À̵æ
  • secondary gain
    ÀÌÂ÷(Àû) À̵æ(¡­ì¦Ôð).
  • therapeutic gain factor, TGF
    Ä¡·áÀ̵æ°è¼ö
  • time gain compensation
    ½Ã°£ (ãÁÊà) °ÔÀÎ º¸»ó (ÜÍßÁ)
  • time gain compensation
    ½Ã°£ °ÔÀÎ º¸»ó
  • time gain compenstaion curve
    ½Ã°£ (ãÁÊà) °ÔÀÎ º¸»ó °î¼± (ÜÍßÁ ÍØàÊ)
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antigenic gain
    Ç׿ø¼º Áõ°¡(ù÷ê«àõñòÊ¥)
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • GaIN
    (å²) galactosamine
  • antigenic competition
    Ç׿ø°æÇÕ(ù÷ê«Ìæùê)
  • antigenic conversion
    Ç׿øÀüȯ(ù÷ê«ï®üµ)
  • antigenic deletion
    Ç׿ø°á¼Õ(ù÷ê«ÌÀáß)
  • antigenic determinant
    Ç׿ø°áÁ¤¼Ò(ù÷ê«Ì½ïÒáÈ)
  • antigenic drift
    Ç׿ø¼º Ç¥·ù(ù÷ê«àõø÷×µ)
  • antigenic modulation
    Ç׿øÁ¶Á¤(ù÷ê«ðàïÚ)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • AGC [=automatic gain control]
    ÀÚµ¿°ÔÀÎÁ¶Àý
  • depth gain compensation
    ±íÀ̰ÔÀÎ(°­µµ)º¸»ó
  • far gain
    ¿ø°Å¸®°ÔÀÎ
  • gain
    °ÔÀÎ
  • near gain
    ±Ù°Å¸®°ÔÀÎ
  • T.G.C [=time gain compensation]
    ½Ã°£°ÔÀκ¸»ó
  • time gain compensation [=T.G.C.]
    ½Ã°£°ÔÀκ¸»ó
  • time gain compenstaion curve
    ½Ã°£°ÔÀκ¸»ó°î¼±
  • time gain control
    ½Ã°£°ÔÀÎÁ¶Àý
  • total gain
    ÃѰÔÀÎ
  • weight gain
    üÁßÁõ°¡
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
MAD Major Antigenic Determinant
AD accident dispensary; acetate dialysis; active disease; acute dermatomyositis; addict, addiction; ade...
NAD neutrophil actin dysfunction; new antigenic determinant; nicotinamide adenine dinucleotide; nicotini...
AGC Automatic Gain Control
AGC absolute granulocyte count; automatic gain control
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
MAP Multiple Antigenic Peptide
VAT variant antigenic type
AGC Automatic Gain Control
ADG Average daily gain
BWG Body weight gain
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • antigenic assay
    Ç׿ø¼º ºÐ¼®
  • antigenic specificity
    Ç׿ø ƯÀ̼º
  • antigenic suicide
    Ç׿ø¿¡ ÀÇÇÑ ¸²ÇÁ±¸ÀÇ ÀÚ¸ê
    °íµµ·Î ¹æ»ç Ȱ¼ºÀÌ ÀÖ´Â Ç׿øÀ» »ýü¿¡ Åõ¿©Çϸé ÀÌ Ç׿ø¿¡ ´ëÇÏ¿© °¨¼ö¼ºÀÌ ÀÖ´Â ¸²ÇÁ±¸´Â °¨¼Ò ³»Áö ºÒȰ¼ºÈ­µÇ¾î ¹ö¸°´Ù. µû¶ó¼­ ¹æ»ç Ȱ¼ºÀÌ ¾ø´Â °°Àº Ç׿øÀ» Åõ¿©Çصµ ÀÌ Ç׿ø¿¡ ƯÀÌÀûÀÎ ¸é¿ª ÀÀ´äÀº »ý±âÁö ¾Ê°Ô µÈ´Ù. À̰ÍÀº Ç׿ø¿¡ ¹ÝÀÀÇÏ´Â ¸²ÇÁ±¸°¡ ¹æ»ç Ȱ¼ºÀÌ ÀÖ´Â Ç׿øÀ» °áÇÕ½ÃÅ´À¸·Î½á ¹æ»ç´É¿¡ ÀÇÇÑ ¼¼Æ÷ ¼Õ»óÀ» ÀԾ ¾ß±âµÇ´Â °ÍÀÌ´Ù. À̰ÍÀ» Ç׿ø¿¡ ÀÇÇÑ ¸²ÇÁ±¸ÀÇ ÀÚ¸êÀ̶ó°í ÇÑ´Ù.
  • near gain
    ±Ù°Å¸® °ÔÀÎ
  • organ gain access
    ±âÁú À̵æ Á¢±Ù
  • primary gain
    ÀÏÂ÷ À̵æ
  • secondary gain
    ÀÌÂ÷ À̵æ
    °£Á¢ÀûÀÎ À̵æÀ¸·Î¼­ º¸Åë Áúº´À̳ª ¼è¾àÀ¸·ÎºÎÅÍ ¾ò¾îÁø´Ù. À̰ÍÀº Àڽſ¡°Ô ÇØ·Î¿î Àǹ«³ª Ȱµ¿À» ÇÇÇϰí Åë»óÀûÀ¸·Î´Â µµ¿ÍÁÖÁö ¾Ê´Â »ç¶÷À¸·ÎºÎÅÍ ÁöÁö¸¦ ¹ÞÀ» ¼ö ÀÖµµ·Ï ÇÑ´Ù.
  • time gain compensation
    ½Ã°£ °ÔÀÎ º¸»ó
  • time gain control
    ½Ã°£ °ÔÀÎ Á¶Àý
  • weight gain
    üÁß Áõ°¡
    °ú´ÙÇÑ À½½ÄÀÇ ¼·Ãë, ¿îµ¿À¸·Î ÀÎÇÑ ±ÙÀ°ÀÇ Áõ°¡, º´Àû »óȲ µîÀÇ ¿øÀÎÀÌ ÀÖÀ¸³ª º¸Åë °ú½ÄÀ¸·Î ÀÎÇÑ Ã¼Áö¹æÀÇ Áõ°¡ ¶Ç´Â º´À¸·Î ÀÎÇÑ Ã¼ÁßÁõ°¡ µîÀÇ ¶æÀ¸·Î ³ª»Ú°Ô ¾²ÀδÙ.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
gain <physics> (Amplification) Increase in a signal transmitted from one point to another through an amplifier.
(09 Oct 1997)
weight gain Increase in body weight over existing weight.
(12 Dec 1998)
primary gain Interpersonal, social, or financial advantages from the conversion of emotional stress directly into demonstrably organic illnesses (e.g., hysterical blindness or paralysis).
Compare: secondary gain.
(05 Mar 2000)
secondary gain Interpersonal or social advantages (e.g., assistance, attention, sympathy) gained indirectly from organic illness.
Compare: primary gain.
(05 Mar 2000)
time-compensated gain In ultrasonography, an increase in receiver gain with time to compensate for loss in echo amplitude with depth, usually due to attenuation.
Synonym: attenuation compensation, depth compensation, time compensation gain, time-compensated gain, time-varied gain control, time-varied gain.
(05 Mar 2000)
time compensation gain In ultrasonography, an increase in receiver gain with time to compensate for loss in echo amplitude with depth, usually due to attenuation.
Synonym: attenuation compensation, depth compensation, time compensation gain, time-compensated gain, time-varied gain control, time-varied gain.
(05 Mar 2000)
time-gain compensation In ultrasonography, an increase in receiver gain with time to compensate for loss in echo amplitude with depth, usually due to attenuation.
Synonym: attenuation compensation, depth compensation, time compensation gain, time-compensated gain, time-varied gain control, time-varied gain.
(05 Mar 2000)
time-varied gain In ultrasonography, an increase in receiver gain with time to compensate for loss in echo amplitude with depth, usually due to attenuation.
Synonym: attenuation compensation, depth compensation, time compensation gain, time-compensated gain, time-varied gain control, time-varied gain.
(05 Mar 2000)
time-varied gain control In ultrasonography, an increase in receiver gain with time to compensate for loss in echo amplitude with depth, usually due to attenuation.
Synonym: attenuation compensation, depth compensation, time compensation gain, time-compensated gain, time-varied gain control, time-varied gain.
(05 Mar 2000)
antigenic Having the properties of an antigen (allergen).
Synonym: allergenic, immunogenic.
(05 Mar 2000)
antigenic competition Competition that occurs when two different antigens, each of which can evoke an immunological response when inoculated alone, are mixed in equal quantities and inoculated together; the response may be to only one, that to the other being largely or entirely suppressed.
(05 Mar 2000)
antigenic complex A composite of different antigenic structures, such as a cell or a bacterium, or, by extension, a molecule containing two or more determinant groups of different antigenic specificities.
(05 Mar 2000)
antigenic determinant That part of an antigenic molecule against which a particular immune response is directed. For instance a tetra to penta peptide sequence in a protein, a tri to penta glycoside sequence in a polysaccharide.
In the animal most antigens will present several or even many antigenic determinants simultaneously.
See: hapten.
(18 Nov 1997)
antigenic drift <immunology> A change that occurs on the molecular level to effect a change in the antigenicity of a bacteria or virus. Antigenic drift occurs naturally and more rapidly in certain viruses (for example HIV). It is antigenic drift which complicates the development of an effective HIV (AIDS) vaccine.
(27 Sep 1997)
antigenic modulation Loss of detectable antigen from the surface of a cell after incubation with antibodies. This is one method in which some tumours escape detection by the immune system. Antigenic modulation of target antigens also reduces the therapeutic effectiveness of treatment by monoclonal antibodies.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • gain
    ¾ò´Ù,ȹµæÇÏ´Ù,-¿¡ µµ´ÞÇÏ´Ù
  • gain on
    -À» ´É°¡ÇÏ´Ù
  • capital gain
    ÀÚº» ÀÌÀÍ;°íÁ¤ ÀÚ»ê ¸Å°¢¼Òµæ
  • gain
    ÀÌÀÍ;Áõ°¡;Áøº¸;(pl) À̵æ;¹úÀÌ
  • gain
    ÀÌÀÍÀ» ¾ò´Ù;³ª¾Æ°¡´Ù;ÀߵǴÙ;~ (up)on ~¿¡ Á¢±ÙÇÏ´Ù;(¾Æ¹«¿¡°Ô) ºô ºÙ´Ù;~¿¡ ħ½ÄÇÏ´Ù;~ over ¼³º¹½ÃŰ´Ù;(ÀÚ±â ÆíÀ¸·Î)²ø¾îµéÀÌ´Ù
  • gain
    ¾ò´Ù;À̱â´Ù;ȹµæÇÏ´Ù;(¹«°Ô,Èû µîÀÌ)´Ã´Ù;(½Ã°è°¡)´õ °¡´Ù
  • gain control
    (ÀüÀÚ)(¼ö½Å±â,Á߯ø±âÀÇ)À̵æ Á¦¾î
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á